Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma

Leuk Lymphoma. 2010 Sep;51(9):1583-4. doi: 10.3109/10428194.2010.508190.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • Antineoplastic Agents / therapeutic use*
  • CD52 Antigen
  • Glycoproteins / antagonists & inhibitors*
  • Glycoproteins / immunology
  • Humans
  • Immunoblastic Lymphadenopathy / drug therapy*
  • Immunoblastic Lymphadenopathy / immunology
  • Immunoblastic Lymphadenopathy / pathology
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab